BACKGROUND: Upgrade rates of high-risk breast lesions after screening mammography were examined.
Percutaneous image-guided needle biopsies have revolutionized the management of suspicious breast imaging findings. The ability to obtain tissue from mammography, ultrasound, or magnetic resonance imaging findings enables women with benign pathology to avoid surgery, whereas those diagnosed with cancer can be planned for a definitive 1-stage surgery. However, there is 1 group of women who do not gain from this breakthrough: those diagnosed with high-risk breast lesions on needle biopsy. These lesions include atypical ductal hyperplasia (ADH), atypical lobular hyperplasia, lobular carcinoma in situ, papillary lesions (benign papilloma, atypical papillary hyperplasia), radial sclerosing lesions, and columnar lesions. Many will undergo surgery after needle biopsy to achieve a definitive diagnosis and rule out cancer. Those who are upgraded to invasive cancer may need further surgery to achieve negative margins or to stage the axilla. There is great controversy regarding the need for follow-up surgery. Multiple studies and reviews have been published on the surgical results with a wide range of upgrade rates to cancer and hence different recommendations. These reports are limited by the small numbers of women included with a mix of indications for biopsy, by the selection of women for surgery, and by a lack of imaging-pathology correlation. To complicate matters, poor interobserver variability has been reported with these lesions. 1 In addition, there is great variation in physician recommendations; in surveys of surgeons, 2 radiologists, 3 and pathologists, 4 there seemed to be more disagreement then agreement on the management of some of these lesions. This problem will only increase with the increased use of newer imaging technologies such as magnetic resonance imaging, breast tomosynthesis, and molecular breast imaging.
Large population-based studies with adequate follow-up of women who did and those who did not have surgery are needed to resolve these questions. We used data from the Breast Cancer Surveillance Consortium (BCSC) to examine the rates of upgrade of high-risk lesions in this populationbased cohort.
Methods
We included data from 5 mammography registries that participate in the National Cancer Institute-funded BCSC (http://breastscreening.cancer.gov): the Carolina Mammography Registry, Group Health Cooperative in Washington, the New Hampshire Mammography Network, the New Mexico Mammography Project, and the Vermont Breast Cancer Surveillance System. These registries collect information on mammographic examinations done in their defined catchment areas. Each mammography registry annually links women in its registry to a state tumor registry or regional Surveillance, Epidemiology and End Results program that collects population-based cancer data and pathology databases that collect information on both benign and malignant diagnoses. The BCSC Statistical Coordinating Center pooled and analyzed the data. Each mammography registry and the Statistical Coordinating Center have received institutional review board approval for either active or passive consenting processes or a waiver of consent to enroll participants, link data, and perform analytic studies. All procedures comply with the Health Insurance Portability and Accountability Act, and all registries and the Statistical Coordinating Center have received federal certificates of confidentiality and other protection for the identities of women, physicians, and facilities studied by this research.
The study sample included screening mammographic examinations and short-interval follow-up examinations done between January 1, 1994, and December 31, 2007, on women aged R40 years. To avoid misclassifying diagnostic examinations as screening examinations, we excluded examinations done within 9 months of a prior breast imaging examination. Short interval follow-up examinations were defined by the indication given by the radiologist. Breast Imaging Reporting and Data System (BI-RADS) category 5 exams were excluded from the study. Mammography examinations that occurred after 2007 were not included to ensure R12 months for reporting cancers to tumor registries after the most recent mammographic examination.
A self-administered questionnaire included questions about family history of breast cancer (first-degree relative), time since previous mammography, menopausal status, and current use of postmenopausal hormone treatment. Time since previous mammography was classified as ,1 year (9 to 11 months), 12 to 35 months, 36 to 59 months, R5 years, or no previous mammography.
Pathologic data included pathologic results for the first needle biopsy within 4 months of mammography and for all surgical biopsies (including excisional biopsies, lumpectomies, and mastectomies) done on the same side within 6 months of the needle biopsy. Fine-needle aspiration specimens were excluded.
Pathology results were classified as ADH, lobular neoplasia (atypical lobular hyperplasia, lobular carcinoma in situ), papillary lesions (intraductal papilloma, multiple papillomas), or cancer (ductal carcinoma in situ [DCIS] or invasive cancer). Papillary lesions with atypia were combined with ADH lesions. Data on papillary lesions and radial sclerosing lesions were available from 2 registries. Radial sclerosing lesions were excluded because there were too few. Because complete cancer ascertainment is available for the women in the BCSC, to determine if high-risk lesions were upgraded to cancer (,1 year after needle biopsy), all women, regardless of documented surgery, were included, though cancer was rare in women without follow-up surgery. Two-year and 3-year follow-up was available for 749 (78%) and 678 (71%) of the study subjects, respectively.
Cancers were classified according to their grade and American Joint Committee on Cancer 6th edition 5 stage at diagnosis. Invasive cancers were classified according to their histology.
Statistical analysis
Associations between characteristics of women and the likelihood of having documented follow-up surgery within 6 months on the same side were examined using logistic regression adjusting for registry. Rates of upgrade to cancer were calculated for each lesion type according to age, family and personal breast cancer history, type of mammography, time since last mammography, year of mammography, and mammographic breast density. Significance of associations was examined using logistic regression adjusting for BCSC registry. Variables that were associated with upgrade rates at the .10 level were included in a multivariate model adjusting for age and registry. Because high-risk lesions and cancer can be influenced by the presence of endogenous and exogenous hormones, data were stratified by menopausal status. We examined the time to cancer diagnosis among women with and without followup surgery using Kaplan-Meier survival curves.
Results
The entire sample included 3,981,045 screening or short-interval follow-up mammograms, 54,386 (1.4%) of which were assigned BI-RADS category 4 final assessments ( cancer and 1,224 (5%) with high-risk lesions. After restricting to needle biopsies done on the same side as the positive BI-RADS assessment and exclusion of radial sclerosing lesions, 957 women were included in the study group. Most (n 5 685) of these had ADH, 173 were diagnosed with lobular neoplasia, and 99 had benign papillary lesions. Five hundred seven (53%) underwent follow-up surgery on the same side and documented within 6 months of the needle biopsy (Table 1) . Among women with high-risk lesions, younger women were more likely to undergo surgery. Type of high-risk lesion was associated with undergoing follow-up surgery, with 61% of women with ADH compared with only 19% of women with papillary lesions undergoing surgery within 6 months. Overall, 18% of women (n 5 123) with ADH, 10% of women (n 5 18) with lobular neoplasia, and 2% of women (n 5 2) with papillary lesions were upgraded to cancer (Table 2 ). In women with ADH on needle biopsy, increased upgrade rates were seen in those who had follow-up surgery within 6 months of the needle biopsy (26% vs 5%) and in women not on hormone treatment. On multivariate analysis, higher rates of upgrade were seen in premenopausal women with family histories of breast cancer (45% vs 19% in those with no family histories) and in postmenopausal women with no use of hormone treatment (18% vs 11%) ( Table 3 ). In women with lobular neoplasia, upgrade was significantly associated with follow-up surgery done within 6 months (25% in women with documented surgery vs 2% in those with no documented surgery within 6 months). Only 2 women (2%) with papillary lesions were upgraded to cancer.
One hundred fifty-three women were diagnosed with cancer within 1 year of needle biopsy (Table 4) . Most of the women with ADH on needle biopsy who were upgraded to cancer were found to have DCIS (n 5 101 [82%]). However, more than half (n 5 10 [56%]) of the women with lobular neoplasia who were upgraded to cancer were found to have invasive carcinoma, with lobular cancer found in 60% of these women. Most women with invasive carcinoma had grade 1 or 2 cancers, and most were diagnosed at an early stage (stage I or II). Lymph nodes were involved more often in the women who were first diagnosed with lobular neoplasia compared with those with ADH (20% vs 5%). The 2 women with papillary lesions upgraded to cancer were diagnosed with DCIS.
Women who did not undergo surgery as well as those who did remained at low risk for developing cancer during follow-up (Fig. 2) . During the 1st year, breast cancer was documented in 25% of all women with high-risk lesions undergoing excisional biopsy and in 4% of those with no excisional biopsy documented. Among women with no cancer within 1 year of needle biopsy, during an additional 2 years follow-up, cancers were documented in 4 women (1%) who underwent follow-up surgery and in 11 women (3%) who had no documented surgery in the first 6 months. Most of the cancers diagnosed after the 1st year were invasive (n 5 9 [60%]).
Comments
On the basis of our findings, approximately 24 of every 100,000 screening mammograms will lead to needle biopsies with diagnoses of high-risk breast lesions. Our estimates may be slightly low because in the earlier years of the study, many of the first biopsies were open biopsies, and only needle biopsies were included in this study. More than half of these women will subsequently undergo surgery, with approximately 4 (0.004%) upgraded to cancer.
Atypical ductal hyperplasia
We found that premenopausal women with family histories of breast cancer were more likely to have upgrades to cancer than those without family histories. In postmenopausal women, not using hormone treatment was associated with upgrade to cancer. The reverse association between hormone treatment use and upgrade to cancer is not easily explained and could be a chance finding. Because hormone use is associated with increased risk for ADH and breast cancer, 6 we cannot recommend that women on hormone treatment diagnosed with ADH on needle biopsy not undergo follow-up surgery. We were unable to characterize women who can safely avoid surgery after a needle biopsy diagnosis of ADH. Multiple studies report on rates of upgrade in women with needle biopsy diagnoses of ADH with rates ranging widely between 7% and 87%. 7 Several studies have attempted to identify factors associated with increased rates of upgrade to malignancy. In 1 study, age was associated with upgrade. 8 There is an association between the extent of sampling (determined by type of needle, number of specimens procured, and residual findings on postbiopsy imaging) and rate of upgrade to cancer. 9 Pathologic characteristics associated with upgrade are the extent of ADH, 10 the presence of severe atypia, 11 micropapillary pattern, 10 and associated necrosis. 11 Most studies recommend surgery after an ADH diagnosis; however, only 61% of our ADH cohort underwent surgery, with an overall upgrade rate of 18%. Therefore, these women should be managed individually on the basis of their family histories, imaging findings, extent of sampling, and pathologies findings.
Lobular neoplasia
In this study, limited to asymptomatic women with BI-RADS category 4 mammograms, the upgrade rate was 10% for lobular neoplasia; however, more than half were upgraded to invasive carcinoma. The literature is inconclusive in recommending follow-up surgery for these lesions. There are several reasons for this lack of a consistent recommendation. Studies are limited by their retrospective designs, usually including only small numbers of patients who underwent follow-up surgery. It is not clear if atypical lobular hyperplasia and lobular carcinoma in situ should be approached separately 12 or as 1 entity as similar rates of upgrade were reported. 13 To add to the confusion, there is a debate on the ability of lobular neoplasia to cause an imaging abnormality such as calcifications or mass. Classically, lobular neoplasia was considered an incidental finding with no imaging correlate. 14, 15 Recently, this dogma has been questioned. 3 Surgery rates are lower for lobular neoplasia compared with ADH; in this report, 39% had follow-up surgery, although a rate of 71% was reported in a multicenter study. 13 In most studies, no followup is available for women not undergoing surgery. 16, 17 In early studies, in which no imaging-pathologic correlation was done, high rates of upgrade were reported (14% to 50%) 12 ; in recent years, several studies have reported very low rates of upgrade in patients in whom the imaging abnormalities were correctly biopsied and the highest abnormality was lobular neoplasia. 18, 19 Our results show that physicians are correctly selecting women for surgery, as most do not undergo surgery, and follow-up rates of cancer are low.
Papillary lesions
In this study, papillary lesions (without atypia) found on needle biopsy of mammographic abnormalities were associated with a 2% rate of upgrade to cancer, which in both cases was DCIS. This rate falls within the acceptable range of the BI-RADS category 3 assessment, recommending shortinterval follow-up. 20, 21 Moreover, in the studies that defined the BI-RADS category 3 assessment, upgrade to cancer was defined only when invasive cancer was diagnosed during follow-up, not carcinoma in situ or atypical hyperplasia.
22
Other studies have reported rates of upgrade ranging between 0% and 29%. 12 There are several reasons for these large variations. The literature is a mix of mostly retrospective studies of both symptomatic and screening-associated findings diagnosed on different imaging modalities using different biopsy techniques with no or limited follow-up of the women not undergoing surgery. Several studies found an association with age 23, 24 or the size of the lesion. 25 We included all cases of benign papillomas diagnosed in asymptomatic women undergoing screening mammography, most of whom (81%) did not undergo excisional biopsy. However, because follow-up was available for most of the study group, we are able to show that the rate of cancer after 3 years of followup was low. Of 89 papillary lesions with 3 years of followup, 1 was diagnosed with cancer in 1 year, and 2 additional were diagnosed within 3 years. Similarly, Sohn et al 26 reported that 1.1% of benign papillomas developed into cancer during mean follow-up period of 53 months. It is important to understand that these results are limited to asymptomatic women with benign papillary lesions diagnosed on needle biopsy of a BI-RADS category 4 mammogram and cannot be generalized to all women with needle biopsy diagnoses of benign papilloma. Despite a low overall rate of follow-up surgery (53%), rates of cancer documented during an additional 2 years of follow-up, for women with no cancer diagnosis during the 1st year after needle biopsy, were low (3% in women with no documented follow-up surgery within 6 months of biopsy vs 1% in those undergoing surgery). These rates are comparable with those calculated using the Gail model risk calculator 27 for a 55-year-old woman with atypical hyperplasia on biopsy: 3% risk over 5 years compared with 1.5% in an average woman.
This study had several limitations. Data in the BCSC registry on family history are limited to first-degree relatives with breast cancer. We were unable to individually correlate radiology findings with pathology results or to review pathology slides. No information was available on the number of cores, needle size, targeted lesion size, the amount of atypia present in the specimen, or the criteria for excision. Follow-up surgery rates are probably an underestimation because some cancers were documented within 6 months of needle biopsy in women with no documented follow-up surgery via linkage with cancer registries.
The design of this study is unique in that it is population and screening based, from a consortium of registries from several states, including detailed data that allowed us to examine the association of upgrade with personal risk factors. As cancer catchment is accurate for the entire study group, we were able to examine the actual rates of cancer development in this population during follow-up.
Although published surveys show large variability in management of high-risk lesions, our results show that physicians are selectively managing these lesions, and judging by 3-year follow-up cancer rates, they appear to be able to identify women at low risk for breast cancer after a high-risk breast biopsy. Therefore, physicians should continue to manage these lesions on a case-by-case basis, with continuous communication among surgery, radiology, and pathology. There cannot be a general recommendation that will fit all cases on the basis of this study.
